From both in vitro analysis of human GBM samples and in vivo GBM xenograft studies, we provide evidence that reduction of SON triggers multiple changes in PTBP1- and RBFOX2-mediated alternative splicing programs, resulting in a reduction in GBM cell growth and eradicating stemness of GSCs (models in Fig. 9). The gene discussed is SON; the disease is glioblastoma.